Third Circuit rescues Fresenius Kabi’s monopolisation claims against Par

An appellate court has revived drug manufacturer Fresenius Kabi’s antitrust lawsuit against Par Pharmaceutical, determining that a lower court in New Jersey failed to conduct a requisite analysis of the issues in the case.


Get unlimited access to all Global Competition Review content